Publications by authors named "F McErlane"
Objective: We aimed to study the disease course, outcomes, and predictors of outcome in pediatric-onset antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) affecting the kidneys.
Methods: Patients eligible for this study had a diagnosis of granulomatosis with polyangiitis (GPA), microscopic polyangiitis, or ANCA-positive pauci-immune glomerulonephritis, were 18 years or younger at diagnosis, had renal disease defined by biopsy or dialysis dependence, and had clinical data at diagnosis and at either 12 or 24 months. Ambispective data from A Registry for Children with Vasculitis/Pediatric Vasculitis Initiative Registry was used.
Article Synopsis
- The study compares the effectiveness and toxicity of two treatments, rituximab (RTX) and cyclophosphamide (CYC), for pediatric patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).
- It analyzes data from 104 patients and finds no significant difference in remission rates or severe adverse events between the two treatment groups.
- Limitations of the study include the lack of standardized treatment protocols and the retrospective nature of the analysis.
Objective: The goal was to assess the degree of overlap between existing International League of Associations for Rheumatology (ILAR) and preliminary Paediatric Rheumatology International Trials Organisation (PRINTO) classification criteria for juvenile idiopathic arthritis (JIA).
Methods: Participants from the Childhood Arthritis Prospective Study, a multicenter UK JIA inception cohort, were classified using the PRINTO and ILAR classification criteria into distinct categories. Systemic JIA was excluded because several classification items were not collected in this cohort.
Background: This study aimed to elicit and quantify preferences for treatments for juvenile idiopathic arthritis (JIA).
Methods: We conducted a discrete-choice experiment among adolescents with JIA in the United States (US) (n = 197) and United Kingdom (UK) (n = 100) and caregivers of children with JIA in the US (n = 207) and UK (n = 200). In a series of questions, respondents chose between experimentally designed profiles for hypothetical JIA treatments that varied in efficacy (symptom control; time until next flare-up), side effects (stomachache, nausea, and vomiting; headaches), mode and frequency of administration, and the need for combination therapy.
Article Synopsis
- The study examines the unique clinical features of Juvenile Psoriatic Arthritis (JPsA) in comparison to other types of Juvenile Idiopathic Arthritis (JIA) and how these features affect patient-reported outcomes and overall clinical results.
- Researchers analyzed data from children and young adults diagnosed with JPsA and other JIA types over a period spanning nearly two decades, using various assessment tools to gauge health and wellbeing.
- Findings revealed no significant differences in initial patient-reported outcomes between JPsA and non-JPsA cases, but JPsA patients with psoriasis experienced more depressive symptoms, indicating a need for integrated care that addresses both physical and psychological health in affected individuals.